CMS
  • Partnering
  • Contact
    • Contact Information
    • Join Us
  • EN
  • CN
  • About Us
    • CMS Overview
    • Leadership
    • Milestones
    • Social Responsibility
  • Innovation
    • R&D Overview
    • Pipeline
  • Business
    • Business Overview
    • Cardio-cerebrovascular and Gastroenterology
    • Dermatology and Medical Aesthetics
    • Ophthalmology
    • Consumer Healthcare
  • News
    • Company News
    • Partner News
  • Investors
    • Stock Infomation
    • Financial Highlights
    • Information Disclosure
    • Corporate Governance
    • Investor Communication
  • Home
  • About Us
    • CMS Overview
    • Leadership
    • Milestones
    • Social Responsibility
  • Innovation
    • R&D Overview
    • Pipeline
  • Business
    • Business Overview
    • Cardio-cerebrovascular and Gastroenterology
    • Dermatology and Medical Aesthetics
    • Ophthalmology
    • Consumer Healthcare
  • News
    • Company News
    • Partner News
  • Investors
    • Investors
    • Stock Infomation
    • Financial Highlights
    • Information Disclosure
    • Corporate Governance
    • Investor Communication
  • Partnering
  • Contact
    • Contact Information
    • Join Us
  • EN
  • CN
Information Disclosure

Information Disclosure

  • Announcements and Circulars
  • Financial Reports
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2023
2023-02-01
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2022
2023-01-03
Voluntary and Business Update Announcement Gaining Exclusive License for Ruxolitinib Cream for the Treatment of Vitiligo and Atopic Dermatitis
2022-12-02
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2022
2022-12-01
Next Day Disclosure Return
2022-11-24
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2022
2022-11-01
Next Day Disclosure Return
2022-10-12
Voluntary and Business Update Announcement Gaining Exclusive License for BMI Botulinum Toxin Product
2022-10-07
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2022
2022-10-07
Next Day Disclosure Return
2022-09-29
Page 1 of 50
  • 1
  • 2
  • 3
  • 4
  • ›
  • »
  • About Us
    • CMS Overview
    • Leadership
    • Milestones
    • Social Responsibility
  • Innovation
    • R&D Overview
    • Pipeline
  • Business
    • Business Overview
    • Cardio-cerebrovascular and Gastroenterology
    • Dermatology and Medical Aesthetics
    • Ophthalmology
    • Consumer Healthcare
  • News
    • Company News
    • Partner News
  • Investors
    • Stock Infomation
    • Financial Highlights
    • Information Disclosure
    • Corporate Governance
    • Investor Communication
  • Partnering
  • Contact
    • Contact Information
    • Join Us
  • Privacy
  • Terms Of Use
All rights reserved by CMS Group 2001-2022 ERP of CMS Group
互联网药品信息服务资格证书编号:(粤)-非经营性-2021-0109| 粤ICP备18157737号| 粤公网安备 44030502003605号